Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lonaprisan

An orally bioavailable pentafluoroethyl derivative of a mifepristone-related steroid with antiprogestagenic activity. Lonaprisan is a pure, highly receptor-selective progesterone receptor (PR) antagonist; binding of this agent to PRs inhibits PR activation and the associated proliferative effects. Unlike many other antiprogestins such as mifepristone, this agent does not appear to convert to an agonist in the presence of protein kinase A (PKA) activators and shows high antiprogestagenic activity on both progesterone receptor (PR) isoforms PR-A and PR-B.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:progesterone receptor antagonist ZK 230211
Code name:ZK 230211
Chemical structure:11β-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17-hydroxy-19-nor-17α-pregna-4,9- dien-3-one
19-norpregna-4,9-dien-3-one, 11-(4-acetylphenyl)-20,20,21,21,21-pentafluro-17- hydroxy-, (11β,17α)-
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search